翰宇药业：与博瑞医药达成战略合作 共推多肽原料药商业化生产

Core Viewpoint - The company is actively advancing its innovative drug development, particularly in the area of weight loss medications and strategic partnerships for peptide drug commercialization [1] Group 1: Innovative Drug Development - The company has made significant progress in the research and development of innovative drugs, particularly in the CRDMO (Contract Research, Development, and Manufacturing Organization) sector [1] - A strategic cooperation was established with Borui Pharmaceutical on July 31, aiming to leverage each other's strengths in peptide drug development and commercialization [1] - The company is focused on resource sharing and collaborative development to enhance the commercialization of peptide active pharmaceutical ingredients and related overseas submissions [1] Group 2: Weight Loss Drug Advantages - The company's proprietary weight loss drug project, HY3003, has completed the process development for the active pharmaceutical ingredient and is exploring three dosage forms: monthly, weekly, and oral [1] - The clinical development for the HY3000 nasal spray has reached the Phase III stage [1] - The company is collaborating with Sinopharm on the research and development of Cannabidiol (CBD) for CNS (Central Nervous System) applications [1]